

19 Dec 2016 | **Opinion**

Top Financing Of 2016: Cast Your Vote!

by Nancy Dvorin

It's time once again for *In Vivo*'s **Deal of the Year** contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to *pick the winners*. (It's free.)

In Vivo's Top Financing Of 2016 –The Nominees Are:

Another Big Round For Moderna: The \$474 million equity financing that the mRNA drug developer raised in September will cover R&D, manufacturing and pipeline expansion costs until it has proof-of-concept data in hand and can go public. [See Deal]

Grail Spins Out Of Illumina: In January, liquid biopsy play Grail Bio raised a \$100 million-plus Series A round from top-flight investors, including majority owner Illumina. In December, Grail announced it's on the hunt for another \$1.7 billion to fund a clinical trial in half a million people. [See Deal]

Corporate Venture Bolsters Akili: Merck Ventures and Amgen Ventures participated in Akili Interactive Labs' \$42 million multi-tranche Series B round in 2016. The proceeds will fuel development of Akili's clinically-validated video game for assessing and treating cognitive disorders. [See Deal]

Samsung BioLogics' \$2 Billion IPO: The November IPO, the third largest in South Korea's history, is a big validation for biologics development in that country and also shows the importance of diversification for parent Samsung. [See Deal]

DalCor Pharma Gets \$100 Million For CETP Inhibitor: Hoping for better luck than its big pharma counterparts have had with CETP inhibitors, Dalcor closed a \$100 million Series B round to fund Phase III trials of dalcetrapib (licensed from Roche, which terminated it for lack of efficacy) in a genetically distinct group of patients with acute coronary syndrome. [See Deal]



<u>CLICK HERE To Cast Your Vote For The Most Significant Financing</u> <u>Of 2016</u>

<u>CLICK HERE to Cast Your Vote For The Most Significant Strategic</u> <u>Alliance Of 2016</u>

Coming Up Next In IVDOTY16: Top M&A